Eikon Therapeutics is a clinical-stage biotechnology company that combines live-cell super-resolution microscopy with drug discovery and development. Its platform visualizes how proteins move inside living cells to inform candidate selection, with a pipeline focused largely on oncology and related indications. Lead programs include agents studied in advanced melanoma and non-small cell lung cancer; commercial revenue remains minimal while assets advance in the clinic.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q4 2024 | 0 | — | -64.9 | — |
| Q1 2025 | 0 | — | -74.5 | — |
| Q4 2025 | 0 | — | -79.7 | — |
| Q1 2026 | 0 | — | -83 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: MasterCraft Boat Holdings, Inc. (MCFT), Civista Bancshares, Inc. (CIVB), D. Boral Acquisition I Corp. (DBCA), Investors Title Company (ITIC), Nexxen International Ltd. (NEXN), Kura Sushi USA, Inc. (KRUS)